MedX Reports Progress towards DermSecureTM Launch in Brazil
07 October 2019 - 11:00PM
Business Wire
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX)
experienced strong interest for its SIAscopy on DermSecureTM
platform from physicians and dermatologists in Brazil during the
recent 74th Congress of the Brazilian Society of Dermatology held
in Rio de Janeiro in September 2019. MedX representatives attended
to support the large team of sales reps working with the Company’s
Brazilian distribution partners at a MedX branded booth at the
show, demonstrating the benefits of the platform to the Brazilian
dermatologic community in advance of a launch of the product once
regulatory approval is attained.
“We are excited and impressed by the commitment and investment
being made by our Brazilian distribution partners in the
pre-marketing phase in introducing the DermSecureTM platform to
this large and important market,” noted Scott Spearn, CEO of
MedX.
“The acceptance of the SIAscopy on DermSecureTM platform at the
conference was above our greatest expectations,“ noted Fabio
Candello, with the CBD Vida team that will be distributing the
product in Brazil. “More than 1,200 Dermatologists and other
Specialized Doctors visited our MedX booth to interact with and
evaluate this game-changing technology, resulting in more than 200
doctors expressing significant and immediate interest in acquiring
MedX’s system. Brazil’s dermatological thought-leaders were in
attendance and were impressed with the imaging capability along
with the integration of the patient information that is gathered
through the DermSecureTM platform allowing for remote assessment of
moles and lesions. We are establishing our own local Medical
Advisory Board that is familiar with the unique challenges of the
Brazilian market.”
Mr. Candello continued, “We expect a growing interest in
DermSecureTM as our team of 50 sales reps across the country begin
following up with the many doctors that attended the show and
anticipate significant orders once the technology is approved and
awareness of the technology spreads. Brazil has more than 8,000
dermatologists and other doctors specializing in dermatology.
However, serving a population of more than 210 million people is
resulting in long wait times and people being diagnosed with skin
cancer too late, and building a service for assessment with
DermSecure can be a big benefit in Brazil. We are following through
on the final steps required for the product to be approved by the
regulatory body in Brazil, which we anticipate before the end of
the year.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading
medical device and software company focused on skin cancer with its
DermSecure™ telemedicine platform, utilizing its SIAscopy
technology. SIAscopy is also imbedded in its products SIAMETRICS™,
SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485
certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include
hand-held devices that use patented technology utilizing light and
its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then
creating real-time images for physicians and dermatologists to
evaluate all types of moles or lesions within seconds. These
products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide
drug-free and non-invasive treatment of tissue damage and pain.
www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005206/en/
Scott Spearn, President and CEO MedX Health Corp
905-670-4428 ext 229
Medx Health (TSXV:MDX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Medx Health (TSXV:MDX)
Historical Stock Chart
From Jan 2024 to Jan 2025